-
1
-
-
48849083217
-
The REDUCE trial: Chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride
-
Musquera M, Fleshner NE, Finelle A and Zlotta AR: The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride. Expert Rev Anticancer Ther 8: 1073-1079, 2008.
-
(2008)
Expert Rev Anticancer Ther
, vol.8
, pp. 1073-1079
-
-
Musquera, M.1
Fleshner, N.E.2
Finelle, A.3
Zlotta, A.R.4
-
2
-
-
0035060658
-
Treatment of localized prostate cancer with intermittent triple androgen blockade: Preliminary results in 110 consecutive patients
-
DOI 10.1634/theoncologist.6-2-177
-
Leibowitz RL and Tucker SJ: Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients. Oncologist 6: 177-182, 2001. (Pubitemid 32328005)
-
(2001)
Oncologist
, vol.6
, Issue.2
, pp. 177-182
-
-
Leibowitz, R.L.1
Tucker, S.J.2
-
3
-
-
0033045720
-
Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland
-
DOI 10.1002/(SICI)1097-0045(19990701)40:2<105::AID-PROS6>3.0.CO;2-9
-
Kirby R, Robertson C, Turkes A, Griffiths K, Denis LJ, Boyle P, Altwein J and Schroeder F: Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group: Prostat 40: 105-114, 1999. (Pubitemid 29304701)
-
(1999)
Prostate
, vol.40
, Issue.2
, pp. 105-114
-
-
Kirby, R.1
Robertson, C.2
Turkes, A.3
Griffiths, K.4
Denis, L.J.5
Boyle, P.6
Altwein, J.7
Schroder, F.8
-
4
-
-
0037233675
-
Early diagnosis of prostate cancer in finasteride treated BPH patients
-
Tarle M, Kraus O, Trnski D, Reljic A, Ruzic B, Katusic J, Spajic B and Kusic Z: Early diagnosis of prostate cancer in finasteride treated BPH patients. Anticancer Res 23: 693-696, 2003. (Pubitemid 36358474)
-
(2003)
Anticancer Research
, vol.23
, Issue.1 B
, pp. 693-696
-
-
Tarle, M.1
Kraus, O.2
Trnski, D.3
Reljic, A.4
Ruzic, B.5
Katusic, J.6
Spajic, B.7
Kusic, Z.8
-
5
-
-
0036332341
-
Acquired neuroendocrine-positivity during maximal androgen blockade in prostate cancer patients
-
Tarle M, Ahel MZ and Kovacic K: Acquired neuroendocrine-positivity during maximal androgen blockade in prostate cancer patients. Anticancer Res 22: 2525-2529, 2002. (Pubitemid 34857095)
-
(2002)
Anticancer Research
, vol.22
, Issue.4
, pp. 2525-2529
-
-
Tarle, M.1
Ahel, M.Z.2
Kovacic, K.3
-
6
-
-
0035162585
-
Neuroendocrine pathogenesis in adenocarcinoma of the prostate
-
Hansson J and Abrahamsson PA: Neuroendocrine pathogenesis in adenocarcinoma of the prostate. Ann Oncol 12(Suppl 2): S145-152, 2001.
-
(2001)
Ann Oncol
, vol.12
, Issue.SUPPL. 2
-
-
Hansson, J.1
Abrahamsson, P.A.2
-
7
-
-
0028567767
-
Immunohistochemical staining and serotest markers during development of a sarcomatoid and small cell prostate tumor
-
Frkovic-Grazio S, Kraljic I, Trnski D and Tarle M: Immunohistochemical staining and serotest markers during development of a sarcomatoid and small cell prostate tumor. Anticancer Res 14: 2151-2156, 1994.
-
(1994)
Anticancer Res
, vol.14
, pp. 2151-2156
-
-
Frkovic-Grazio, S.1
Kraljic, I.2
Trnski, D.3
Tarle, M.4
-
8
-
-
0035313592
-
High-grade prostate cancer is associated with low serum testosterone levels
-
DOI 10.1002/pros.1046
-
Schatzl G, Madersbacher S, Thuridl T, Waldmuller J, Kramer G, Haitel A and Marberger M: High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47: 52-58, 2001. (Pubitemid 32246752)
-
(2001)
Prostate
, vol.47
, Issue.1
, pp. 52-58
-
-
Schatzl, G.1
Madersbacher, S.2
Thurridl, T.3
Waldmuller, J.4
Kramer, G.5
Haitel, A.6
Marberger, M.7
-
9
-
-
1842788109
-
Neuroendocrine Differentiation in Hormone Refractory Prostate Cancer Following Androgen Deprivation Therapy
-
DOI 10.1016/j.eururo.2003.11.032, PII S0302283804000193
-
Hirano D, Okada Y, Minei S, Takimoto Y and Nemoto N: Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 45: 586-592, 2004. (Pubitemid 38481685)
-
(2004)
European Urology
, vol.45
, Issue.5
, pp. 586-592
-
-
Hirano, D.1
Okada, Y.2
Minei, S.3
Takimoto, Y.4
Nemoto, N.5
-
10
-
-
0033943048
-
Neuropeptides bombesin and calcitonin induce resistance to etoposide induced apoptosis in prostate cancer cell lines
-
Salido M, Vilches J and Lopez A: Neuropeptides bombesin and calcitonin induce resistance to etoposide induced apoptosis in prostate cancer cell lines. Histol Histopathol 15: 729-738, 2000. (Pubitemid 30488556)
-
(2000)
Histology and Histopathology
, vol.15
, Issue.3
, pp. 729-738
-
-
Salido, M.1
Vilches, J.2
Lopez, A.3
-
11
-
-
0037812658
-
The influence of finasteride on the development of prostate cancer
-
DOI 10.1056/NEJMoa030660
-
Thompson IM, Goodman PJ, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM Ryan A, Szcepanek CM, Crowley JJ and Coltman CA Jr: The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 216-224, 2003. (Pubitemid 36859473)
-
(2003)
New England Journal of Medicine
, vol.349
, Issue.3
, pp. 215-224
-
-
Thompson, I.M.1
Goodman, P.J.2
Tangen, C.M.3
Lucia, M.S.4
Miller, G.J.5
Ford, L.G.6
Lieber, M.M.7
Cespedes, R.D.8
Atkins, J.N.9
Lippman, S.M.10
Carlin, S.M.11
Ryan, A.12
Szczepanek, C.M.13
Crowley, J.J.14
Coltman Jr., C.A.15
-
12
-
-
32044457933
-
Do the benefits of finasteride outweigh the risks in the prostate cancer prevention trial?
-
Grover S, Lowensteyn I, Hajek D, Trachtenberg J, Coupal L and Marchand S: Do the benefits of finasteride outweigh the risks in the prostate cancer prevention trial? J Urol 175: 934-938, 2006.
-
(2006)
J Urol
, vol.175
, pp. 934-938
-
-
Grover, S.1
Lowensteyn, I.2
Hajek, D.3
Trachtenberg, J.4
Coupal, L.5
Marchand, S.6
-
13
-
-
67650035960
-
Prolongation of Finasteride therapy may promote aggressive prostate cancer
-
February Vail, Colorado, CD of Abstracts
-
Tarle M, Petek I, Novosel S, Kraljic I, Spajic B and Kusic Z: Prolongation of Finasteride therapy may promote aggressive prostate cancer. 14th International Prostate Cancer Update, February 2004, Vail, Colorado, CD of Abstracts, pp. 1-2.
-
(2004)
14th International Prostate Cancer Update
, pp. 1-2
-
-
Tarle, M.1
Petek, I.2
Novosel, S.3
Kraljic, I.4
Spajic, B.5
Kusic, Z.6
-
14
-
-
0029656028
-
The effect of finasteride on prostate specific antigen: Review of available data
-
Guess AH, Gormley GJ, Stoner E and Oesterling JE: The effect of finasteride on prostate specific antigen: Review of available data. J Urol 156: 3-9, 1996. (Pubitemid 126426420)
-
(1996)
Journal of Urology
, vol.155
, Issue.1
, pp. 3-9
-
-
Guess, H.A.1
Gormley, G.J.2
Stoner, E.3
Oesterling, J.E.4
-
15
-
-
13444280440
-
Effects of finasteride on prostate volume and prostate-specific antigen
-
Chiu KY and Yong CR: Effects of finasteride on prostate volume and prostate-specific antigen. J Chin Med Assoc 67: 571-574, 2004. (Pubitemid 40202069)
-
(2004)
Journal of the Chinese Medical Association
, vol.67
, Issue.11
, pp. 571-574
-
-
Chiu, K.-Y.1
Yong, C.-R.2
-
16
-
-
34547751529
-
Serum tPSA, cPSA, related density parameters and chromogranin a as predictors of positive margins after radical prostatectomy
-
Custovic Z, Kraus O, Tomaskovic I and Tarle M: Serum tPSA, cPSA, related density parameters and chromogranin A as predictors of positive margins after radical prostatectomy. Anticancer Res 27: 2817-2822, 2007. (Pubitemid 47228003)
-
(2007)
Anticancer Research
, vol.27
, Issue.4 C
, pp. 2817-2821
-
-
Custovic, Z.1
Kraus, O.2
Tomaskovic, I.3
Tarle, M.4
-
17
-
-
35348971983
-
Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer
-
Revelos K, Petraki C, Scorilas A, Stefanakis S, Malovrouvas D, Alevizopoulos N, Kanellis G, Halapas A and Koutsilieris M: Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer. Anticancer Res 27(5B): 3651-3660, 2007. (Pubitemid 47607515)
-
(2007)
Anticancer Research
, vol.27
, Issue.5 B
, pp. 3651-3660
-
-
Revelos, K.1
Petraki, C.2
Scorilas, A.3
Stefanakis, S.4
Malovrouvas, D.5
Alevizopoulos, N.6
Kanellis, G.7
Halapas, A.8
Koutsilieris, M.9
-
18
-
-
21844454221
-
Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer
-
DOI 10.1016/j.eururo.2005.03.018, PII S0302283805001521
-
Pucetti L, Supuran CT, Fasolo PP, Conti E, Sebastiani G, Lacquantini S, Mandras R, Milazzo MG, Dogliani N, De Giuli P and Fasolis G: Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer. Eur Urol 48: 215-221, 2005. (Pubitemid 40957091)
-
(2005)
European Urology
, vol.48
, Issue.2
, pp. 215-221
-
-
Puccetti, L.1
Supuran, C.T.2
Fasolo, P.P.3
Conti, E.4
Sebastiani, G.5
Lacquaniti, S.6
Mandras, R.7
Milazzo, M.G.8
Dogliani, N.9
De Giuli, P.10
Fasolis, G.11
-
19
-
-
33846289982
-
New answers from the Prostate Cancer Prevention Trial on the chemoprevention of prostate cancer
-
Ankerst DP and Thompson IM: New answers from the Prostate Cancer Prevention Trial on the chemoprevention of prostate cancer. Arch Ital Urol Androl 78: 154-156, 2006. (Pubitemid 46113694)
-
(2006)
Archivio Italiano di Urologia e Andrologia
, vol.78
, Issue.4
, pp. 154-156
-
-
Ankerst, D.P.1
Thompson, I.M.2
-
20
-
-
0036789162
-
Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma
-
Fixemer T, Remberger K and Bonkhoff H: Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma. Prostate 53: 118-123, 2002.
-
(2002)
Prostate
, vol.53
, pp. 118-123
-
-
Fixemer, T.1
Remberger, K.2
Bonkhoff, H.3
-
22
-
-
34547657069
-
Chemoprevention of prostate cancer: Agents and study designs
-
E pub
-
Thompson IM: Chemoprevention of prostate cancer: agents and study designs. J Urol 178: S9-S13, (E pub), 2007.
-
(2007)
J Urol
, vol.178
-
-
Thompson, I.M.1
|